#FMCG Eight Talks##Consumption##Health#On January 3, according to Tianyancha App data, Zhendong Pharmaceutical, Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Anxin Bio"), Guizhou Yipin Pharmaceutical Chain Co., Ltd. 501 Branch, and Xia recently added a court announcement information, the cause of action is a portrait right dispute, and the plaintiff is Wang Junkai. The case will be heard at 9 a.m. on January 8 at the Baiyun District People's Court in Guiyang City.
Tianyancha announcement did not specifically disclose the infringement matters, and it is understood that the 501 branch of Guizhou Yipin Pharmaceutical Chain Co., Ltd. is a chain pharmacy. Anxin Biotechnology, a subsidiary of Zhendong Pharmaceutical, mainly produces liniments, gels, sprays for external use in dermatology, and tablets and capsules for internal use.
In October 2023, Zhendong Pharmaceutical held the groundbreaking ceremony of the construction project of Zhendong Anxin International Certification Workshop and Scientific Research Center in Jinzhong Development Zone, Shanxi. It will invest 350 million yuan to build an automated intelligent workshop and R&D center in accordance with FDA standards, and build 14 production lines for liniments, solutions, creams, lotions, etc., covering skin external, internal, traditional Chinese medicine, hormones and other fields. The main body of the construction of the project is Anxin Biological, which owns the anti-hair loss brand - Dafeixin, and the industry speculates that the infringement may be related to the product.
In response to the infringement, a reporter from Beijing Business Daily contacted the relevant person in charge of Zhendong Pharmaceutical, and the other party said that the company's advertisements have been reviewed, and the incident is that the store (Guizhou Yipin Pharmaceutical Chain Co., Ltd. 501 Branch) has made a picture by itself.
Zhang Wenbo, a senior partner at Beijing Jundu Law Firm and director of the life sciences and health care legal department, said in an interview with a reporter from Beijing Business Daily that in general, such cases will be settled. If the 501 branch of Guizhou Yipin Pharmaceutical Chain Co., Ltd. has independent business qualifications, Zhendong Pharmaceutical has no intention of joint infringement and does not need to pay money.
The field of hair growth is the direction of Zhendong Pharmaceutical's current focus. Li Anping, chairman of Zhendong Pharmaceutical, said at the groundbreaking ceremony that at present, the company's production of Dafeixin minoxidil liniment is the first in the country in the field of hair shaping, with a growth rate of more than 50% for three consecutive years. Zhendong will take "skin medicine" as the core, and strive to build "the first brand of leather medicine".
Focusing on this core product of Pico, Zhendong Pharmaceutical has formed a "1+5 strategy" anti-hair loss product pattern, of which "1" refers to Dafeixin minoxidil-based drugs, and "5" is for hair follicle detection, treatment, auxiliary massage and hair follicle activation nutrient solution, and shampoo, hair care, and internal hair growth for scalp problems.
Zhendong Pharmaceutical has said that the company plans to increase investment in the market development and marketing of hair loss products Dafeixin, and intends to promote in-depth cooperation with downstream hair transplant companies, choose opportunities to carry out upstream and downstream industrial chain mergers and acquisitions and other strategic measures to achieve the company's active expansion in the field of hair loss treatment.
Zhendong Pharmaceutical is at the crossroads of transformation. Previously, Zhendong Pharmaceutical's sale of Langdi Pharmaceutical, a "cash cow", was puzzling to the market. In 2020, the terminal sales of Langdi Calcium, known as the "King of China's Calcium", reached 4.3 billion yuan, accounting for 88% of Zhendong Pharmaceutical's total revenue. In 2021, Zhendong Pharmaceutical sold Langdi Pharmaceutical, and the net profit attributable to the parent company increased by 898.92% year-on-year that year.
According to Zhendong Pharmaceutical's announcement, the company took into account the future capital investment needs in the fields of hair loss products and innovative drugs and the reduction of debt, so it was sold. However, after the sale, the performance situation took a sharp turn for the worse. In 2022, Zhendong Pharmaceutical's non-net profit will be -148 million yuan, and in the first three quarters of 2023, the non-net profit will be -34 million yuan, and the net profit will both decline.
Zhendong Pharmaceutical has responded that the company's strategic positioning is a "marketing innovation" enterprise, aiming at the field of "dermatology drugs, tumor Chinese medicine, Chinese herbal medicines and APIs", and the layout from APIs to preparations, from imitation to innovation, improve the product pipeline and form field advantages; From warehousing to the establishment and improvement of quality standards, to create a high-standard integrated industrial chain.
From the current point of view, Zhendong Pharmaceutical's hair growth products are difficult to pick. From 2021 to the first half of 2023, Anxin Biotech achieved revenue of 184 million yuan, 227 million yuan, and 133 million yuan respectively, and net profit of 36 million yuan, 69 million yuan, and 45 million yuan.
Beijing Business Daily reporter Yao Qian